Evaro Secures $1.5M Seed Funding to Transform Digital Health with AI-Powered Prescription Services.

Company Name: Evaro
Location: London, UK
Sector: Digital Health - AI-Powered Clinical and Prescription Services
Funding Details: Raised $1.5M in Seed funding, led by Cornerstone VC and Exceptional Ventures, with participation from Catalisi’s investment arm, Syndicate Room, and the University of East Anglia.
Purpose of Investment: To expand into the B2B market, enhance medication catalogue, and acquire Care Quality Commission (CQC) licence for comprehensive patient care.

Leadership: Co-Founders Dr. Thuria Wenbar and Dr. Oskar Wendowski
Product: Evaro offers AI-driven asynchronous consultations and private prescription medication services for minor health conditions. It's distinguished by its use of a machine learning model trained on millions of patient records and a rigorous patient safety process compliant with regulatory standards.

About Company: Evaro provides a cutting-edge solution to the challenge of accessing timely medical consultations and prescriptions. By leveraging AI and ML, Evaro aims to cover 70% of minor health issues typically handled by NHS doctors, significantly expanding its treatment catalogue.

Future Goals:

• B2B Expansion: Offering a plug-and-play product for consumer brands.
• Medication Catalogue Enhancement: Growing from 200 to 2,000 treatments.
• CQC Licence Acquisition: To enable diagnosis and therapy initiation.

Innovative Features:

• AI-Driven Asynchronous Consultations: Streamlines the process of getting medical advice and prescriptions.
• Regulatory-Compliant Patient Safety: Ensures the safety and appropriateness of online treatment requests and drug orders.

CEO’s Vision: The co-founders highlight Evaro's mission to improve access to medical services through technology, emphasizing the importance of safety and regulatory compliance in their innovative approach to healthcare.